Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Esdy N. Rozali
Observed names:
E Rozali,
E. Rozali,
Esdy Rozali
Institution:
QIMR Berghofer Medical Research Institute
Observed institutions:
The University of Queensland,
The University of Western Australia,
QIMR Berghofer Medical Research Institute,
University of Cambridge,
Harry Perkins Institute of Medical Research,
Sir Charles Gairdner Hospital,
Novartis (Singapore),
National Cancer Centre Singapore
show all 8
ORCID:
0000-0003-1032-8467
Observed ORCID:
0000-0003-1032-8467
OpenAlex ID:
A5058374354
Programmed Death Ligand 2 in Cancer-Induced Immune Suppression
2012
·
Esdy N. Rozali
, Stanleyson V. Hato
, et al.
·
Clinical and Developmental Immunology
·
353
PDF
A transcriptome-wide association study of 229,000 women identifies new candidate susceptibility genes for breast cancer
2018
·
NBCS Collaborators
, Lang Wu
, et al.
·
Nature Genetics
·
235
PDF
Synergistic Effect of CTLA-4 Blockade and Cancer Chemotherapy in the Induction of Anti-Tumor Immunity
2013
·
W. Joost Lesterhuis
, Joanne Salmons
, et al.
·
PLoS ONE
·
155
PDF
Programmed cell death-ligand 2: A neglected but important target in the immune response to cancer?
2020
·
Cinzia Solinas
, Marco Aiello
, et al.
·
Translational Oncology
·
105
PDF
Network analysis of immunotherapy-induced regressing tumours identifies novel synergistic drug combinations
2015
·
W. Joost Lesterhuis
, Catherine Rinaldi
, et al.
·
Scientific Reports
·
75
PDF
MEK5-ERK5 pathway associates with poor survival of breast cancer patients after systemic treatments
2015
·
Mariska Miranda
, Esdy Rozali
, et al.
·
Oncoscience
·
42
PDF
Multidimensional phenotyping of breast cancer cell lines to guide preclinical research
2017
·
Jodi M. Saunus
, Chanel E. Smart
, et al.
·
Breast Cancer Research and Treatment
·
41
PDF
Characterization of a novel breast cancer cell line derived from a metastatic bone lesion of a breast cancer patient
2018
·
Julie Johnson
, Darrell C. Bessette
, et al.
·
Breast Cancer Research and Treatment
·
9
ERK5 Mediates Metastatic Colonization and Remodeling of The Tumor and Tumor-Immune Microenvironment and Immunotherapy Response
2025
·
Mariska Miranda
, Oishee Chatterjee
, et al.
·
Fortune Journal of Health Sciences
·
1
Autologous V gamma 9 V delta 2 T cell therapy to target Epstein Barr Virus (EBV)-related malignancies
2019
·
E. Rozali
, C.L.-L. Chiang
, et al.
·
Annals of Oncology
·
1
Defining precision cellular immunotherapy—seeking biomarkers to predict and optimize outcomes of T cell therapies in cancer
2019
·
Shuting Han
, Who-Whong Wang
, et al.
·
Precision Cancer Medicine
·
1
A Short ERK5 Isoform Modulates Nucleocytoplasmic Shuttling of Active ERK5 and Associates with Poor Survival in Breast Cancer
2025
·
Mariska Miranda
, Jodi M. Saunus
, et al.
·
Fortune Journal of Health Sciences
MA10.03 A Cost-Effectiveness Analysis of Actionable Genomic Alteration (AGA) Testing Strategies in Non-Small Cell Lung Cancer (NSCLC)
2023
·
Y. Ang
, M.J.C. Ong
, et al.
·
Journal of Thoracic Oncology
PDF
Abstract P6-09-47: The development of personalized diagnostic tests and therapeutic strategies in breast cancer
2017
·
JR Kutasovic
, E Rozali
, et al.
·
Cancer Research
Abstract P5-04-17: From transcriptome meta-analysis to targeted therapies in triple negative breast cancer
2016
·
E Rozali
, F Al-Ejeh
·
Cancer Research
From transcriptome meta-analysis to targeted therapies in triple negative breast cancer
2016
·
Esdy Rozali
, Fares Al‐Ejeh
·
Cancer Research
Show more works
View as search
Works count:
17
Citation count:
1,018
H-index:
8
I10-index:
7
Year
Topic
Type